Daily Archives: April 21, 2023
2023 ACC expert consensus on management of heart failure with preserved ejection fraction
21 Apr, 2023 | 13:10h | UTCCommentaries:
New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF – TCTMD
RCT | Piperacillin-tazobactam better than cefoxitin in antimicrobial prophylaxis for open pancreatoduodenectomy
21 Apr, 2023 | 13:08h | UTCPiperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Informing a Rational Approach to Antimicrobial Prophylaxis in Open Pancreatoduodenectomy – JAMA (free for a limited period)
Commentary on Twitter
Study findings support the use of piperacillin-tazobactam as perioperative antimicrobial prophylaxis for open pancreatoduodenectomy. https://t.co/M9qAVrePRH pic.twitter.com/xq01qPTHQO
— JAMA (@JAMA_current) April 20, 2023
Study estimates poor diet causes 70% of diabetes cases globally
21 Apr, 2023 | 13:06h | UTCIncident type 2 diabetes attributable to suboptimal diet in 184 countries – Nature Medicine
News Release: Study links poor diet to 14 million cases of type 2 diabetes globally – Tufts University
Commentary on Twitter
An analysis in @NatureMedicine estimates that 70% of new global cases of type 2 diabetes are attributable to suboptimal intake of 11 dietary factors, with substantial differences in dietary risks across world regions and nations. https://t.co/MYoLRt3rhO pic.twitter.com/Pv7I6Mhvxu
— Nature Portfolio (@NaturePortfolio) April 19, 2023
RCT | Pregnant individuals benefit from brief interpersonal psychotherapy for depression
21 Apr, 2023 | 13:05h | UTCCommentary: Interpersonal Psychotherapy Reduces Depression Symptoms of Pregnant Women – HCP Live
Commentary on Twitter
A randomized clinical trial of prenatal interpersonal psychotherapy showed rapid decreases in depression. Depression in the intervention group dropped from 37% before intervention to 6% after (vs. 26% in control group). https://t.co/rJADZZkfER
— JAMA Psychiatry (@JAMAPsych) April 19, 2023
M-A | Electroconvulsive therapy may be superior to ketamine for patients with major depressive episode
21 Apr, 2023 | 13:03h | UTCKetamine vs Electroconvulsive Therapy for Major Depressive Episode: A Systematic Review and Meta-analysis – JAMA Psychiatry (link to abstract – $ for full-text)
Commentaries:
Electroconvulsive Therapy Bests Ketamine in Treating Major Depressive Episodes – HCP Live
Review | The importance of using placebo controls in nonpharmacological randomized trials
21 Apr, 2023 | 13:02h | UTCThe importance of using placebo controls in nonpharmacological randomised trials – Pain
RCT | Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata
21 Apr, 2023 | 13:00h | UTCEfficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial – The Lancet (link to abstract – $ for full-text)
News Release: Progress in search for alopecia areata treatment for adolescents – Yale News
Commentary on Twitter
Ritlecitinib might be a treatment option for alopecia areata in patients aged 12 years and older, suggests a new study: https://t.co/jKUxEbo4AZ
Below, a graphical abstract ? pic.twitter.com/JIJtTGHeE4
— The Lancet (@TheLancet) April 17, 2023
M-A | Adverse events related to tirzepatide (a dual GIP/GLP-1 receptor agonist)
21 Apr, 2023 | 12:59h | UTCAdverse Events Related to Tirzepatide – Journal of the Endocrine Society
Related:
Tirzepatide Once Weekly for the Treatment of Obesity – New England Journal of Medicine
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Study shows that parathyroidectomy in adults with primary hyperparathyroidism probably has no effect on kidney function
21 Apr, 2023 | 12:57h | UTCEstimated Effect of Parathyroidectomy on Long-Term Kidney Function in Adults With Primary Hyperparathyroidism – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentary on Twitter
New: #parathyroidectomy had no effect on long term #KidneyFunction in older adults w/ primary #hyperparathyroidism, but may preserve function in patients under 60. https://t.co/B456rPwGem pic.twitter.com/V8hLmrYiUX
— Annals of Int Med (@AnnalsofIM) April 17, 2023